Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
来自MSN4 天
Canaccord Genuity Downgrades Intra-Cellular Therapies (ITCI)
Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...
Business Insider24 天
Intra-Cellular price target raised to $118 from $100 at BofA
BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...
Intra-Cellular downgraded to Hold from Buy at Canaccord
Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed ...
Small Molecule Drug Discovery Market Growth Expected To Reach USD 121.8 Billion By 2033
The Small Molecule Drug Discovery Market size is expected to be worth around USD 121.8 billion by 2033 from USD 52.5 billion in 2023, growing at a CAGR of 8.8% ...
Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) ...
Investing22 天
Intra-Cellular Therapies stock target raised by Mizuho, Outperform reaffirmed
On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock's price target from $100 to $140 while maintaining an Outperform ...
Investing22 天
Intra-Cellular Therapies stock target raised by Mizuho, Outperform reaffirmed
On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock’s price target from $100 to $140 while maintaining an Outperform ...